Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/28/12 → 3/28/18 |
Funding
- INC Research, LLC (AVL-292-003)
- Avila Therapeutics, Inc. (AVL-292-003)
Prot#AVL-292-003: Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulin
- Ma, Shuo (PD/PI)
Project: Research project